In a European study, in which Amsterdam UMC also participated, a number of promising biomarkers were discovered that can distinguish ‘Lewy body’ dementia from Alzheimer’s disease with high accuracy.
After Alzheimer’s disease, Lewy body dementia is one of the most common forms of dementia in the elderly. The clinical and pathological presentation strongly overlaps with that of Alzheimer’s, leading to missed diagnoses.
The study used advanced proteomic profiling to measure 665 proteins in the cerebrospinal fluid of 109 patients with Lewy Body dementia, 235 patients with Alzheimer’s disease and 190 healthy people.
The researchers identified 50 proteins that appeared to be dysregulated in Lewy Body dementia. The enzyme DOPA Decarboxylase (DDC), which is involved in dopamine biosynthesis, was found to be particularly effective in differentiating Lewy Body dementia from both controls and Alzheimer’s disease. The AUC values were 0.91 and 0.81, respectively.
A biomarker panel of 7 CSF proteins was able to distinguish Lewy Body dementia from Alzheimer’s disease with an AUC as high as 0.93. The panel has been further validated in a number of independent cohorts, opening up opportunities for better diagnosis and treatment of Lewy Body dementia, the researchers said.
On December 12, follow the fifth edition of The Neurological Annual Review, in which Joep Killestein, Teus van Laar, Philip Scheltens and Gisela Terwindt will take you through the most important developments in neurology in the past year.
Bron:
Del Campo M, Vermunt L, Peeters CF, et al. CSF proteome profiling reveals biomarkers to discriminate dementia with Lewy bodies from Alzheimer´s disease. Nat Commun. 2023;14:5635.
2023-10-16 13:34:31
#Biomarkers #distinguish #Lewy #body #dementia #Alzheimers #MedNet
